Investors back cancer treatment firm Biocaptiva – Daily Business

Jeremy Wheeler: vibrant sector

Edinburgh university medical spin-out Biocaptiva has raised £1.58 million to support research and development in its cancer treatment technology and made a key appointment.

Its technology has the potential to improve the pace and scale of cancer research by addressing a long-standing bottleneck in the preparation of liquid samples. It launched its kits for research in Boston earlier this month.

The raise was led by existing investor Archangels, with support from Old College Capital, BBI, Scottish Enterprise, and new investor EverQuest Capital Partners.

Alan Schafer has been appointed chief technology officer, bringing more than 30 years’ experience in genetics technologies and molecular diagnostics.

Jeremy Wheeler, CEO, said: “Oncology is an exciting and vibrant sector. The scientists and technologists have been doing incredible things based upon the samples that they’re given, but there hasn’t been any particular movement in how the samples are prepared for years.

“Our msX platform has the potential to revolutionise how samples are collected, allowing for larger samples, faster extraction, simpler processing, and fully automatable capabilities.

“In practice, that means faster, better and deeper iteration and research on cancer, leading to better outcomes for potentially millions of people globally. This new funding brings us closer to achieving that goal.”

#Investors #cancer #treatment #firm #Biocaptiva #Daily #Business